New Review Reveals Stage-Specific Roles of CHD Proteins in Heart Development, Offering Framework for Understanding Congenital Defects

A comprehensive new review published in World Journal of Pediatrics provides a systematic analysis of how CHD (chromodomain helicase DNA-binding) proteins orchestrate gene expression during heart development, assigning stage-specific roles to different family members. The synthesis, led by a team from China, offers a unifying framework that could explain the origins of congenital heart defects and improve clinical diagnostics.

The review, available at DOI: 10.1007/s12519-026-01049-y, evaluates evidence from human genetics, animal models, and stem-cell systems. The researchers found a clear division of labor: CHD7, most frequently mutated in CHARGE syndrome, plays a dominant role in early structural heart formation; CHD3 and CHD4 act as "identity guardians" during chamber formation; and CHD8 regulates later ventricular growth and functional maturation. While the proteins appear to act at different stages—CHD7 early, CHD4 mid, CHD8 late—the review emphasizes that direct proof of coordinated action is lacking.

"The data show that we cannot treat these proteins as a single, interchangeable group. They have very distinct, stage-specific jobs," the authors said. "For example, CHD7 is the key player in the early morphogenetic events that build the heart's structure, while CHD4 helps lock in the identity of heart cells as they differentiate." The authors propose three testable models for how these remodelers might interact: parallel, sequential, or compensatory.

The findings have direct clinical implications. For genetic screening, the study provides a clear priority: CHD7 for outflow-tract defects, CHD4 for chamber-patterning anomalies, and CHD8 for ventricular dysfunction, which can improve diagnostic efficiency. Therapeutically, while directly targeting remodelers is risky due to their broad expression, identifying downstream pathways—such as those regulating cardiomyocyte proliferation or metabolism—may offer safer drug targets. Future studies combining time-resolved multi-omics and combinatorial genetics could uncover how these proteins coordinate across development, potentially paving the way for precise, temporally controlled epigenetic therapies.